Sector
Healthcare
Industry
Biotechnology
Employees
87
First IPO Date
December 07, 2007
| Name | Title | Pay | Year Born |
| Selwyn | Chief Executive Officer & Chairman of Executive Management Board | 429,000 | 1971 |
| Ernst-Ludwig Winnacker | Co-Founder & Chairman Scientific Advisory Board | 20,000 | 1941 |
| Dolores J. Schendel | Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development | 470,000 | N/A |
| Kirsty Crame | Vice President and Head of Clinical Research & Development | 0 | N/A |
| Pamela Keck | Vice President of Investor Relations & Corporation Communications | 0 | N/A |
| Birger Kohlert | Chief Financial Officer | 0 | N/A |
Medigene AG is a biotechnology firm dedicated to pioneering T cell immunotherapies aimed at combating cancer. Its primary therapeutic thrust involves personalized T cell-based treatments, specifically T cell receptor-modified T cells, which are currently undergoing clinical trials to address significant unmet medical needs. Beyond this core focus, Medigene also explores dendritic cell vaccines and specialized T cell monoclonal antibodies. Diverging from oncology, the company is additionally engaged in the development and commercialization of RhuDex for applications in hepatology and gastroenterology. Collaborations are key to Medigene's strategy; it maintains a strategic alliance with 2seventy bio, Inc. for advancing T cell receptor research. Furthermore, research cooperation agreements are in place with the Université de Montréal and Cytovant Sciences Co. Ltd. to discover and develop novel cancer antigens for immunotherapy. Established in 1994, the company's headquarters are located in Munich, Germany, with its operational footprint spanning Europe, the United States, Asia, and other international regions.